Additionally, both classification systems now recognize TP53-mutated MDS as a distinct, higher-risk entity (‘MDS with biallelic TP53 inactivation’ in WHO and ‘myeloid neoplasms with TP53’ in ICC) [5,6]. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.